ObjectiveSystemic arterial hypertension (HT) is a major modifiable risk factor for cardiovascular disease (CVDs), associated with all-cause death (ACD). Understanding its progression from the early state to late complications should lead to more timely intensification of treatment. This study aimed to construct a real-world cohort profile of HT and to estimate transition probabilities from the uncomplicated state to any of these long-term complications; chronic kidney disease (CKD), coronary artery disease (CAD), stroke, and ACD.MethodsThis real-world cohort study used routine clinical practice data for all adult patients diagnosed with HT in the Ramathibodi Hospital, Thailand from 2010 to 2022. A multi-state model was developed based on the following: state 1-uncomplicated HT, 2-CKD, 3-CAD, 4-stroke, and 5-ACD. Transition probabilities were estimated using Kaplan-Meier method.ResultsA total of 144,149 patients were initially classified as having uncomplicated HT. The transition probabilities (95% CI) from the initial state to CKD, CAD, stroke, and ACD at 10-years were 19.6% (19.3%, 20.0%), 18.2% (17.9%, 18.6%), 7.4% (7.1%, 7.6%), and 1.7% (1.5%, 1.8%), respectively. Once in the intermediate-states of CKD, CAD, and stroke, 10-year transition probabilities to death were 7.5% (6.8%, 8.4%), 9.0% (8.2%, 9.9%), and 10.8% (9.3%, 12.5%).ConclusionsIn this 13-year cohort, CKD was observed as the most common complication, followed by CAD and stroke. Among these, stroke carried the highest risk of ACD, followed by CAD and CKD. These findings provide improved understanding of disease progression to guide appropriate prevention measures. Further investigations of prognostic factors and treatment effectiveness are warranted.

This record contains raw data related to the article: Long-term secondary cardiovascular prevention programme in patients subjected to coronary artery bypass surgery

Abstract

Aims: Patients with coronary heart disease (CHD) are at very high risk of recurrent events. A strategy to reduce excess risk might be to deliver structured secondary prevention programmes, but their efficacy has been mostly evaluated in the short term and in experimental settings. This is a retrospective case-control study aimed at assessing, in the real world, the efficacy of a secondary prevention programme in reducing long-term coronary event recurrences after coronary artery bypass surgery (CABG).

Methods and results: Programme participants (henceforth 'cases') were men and women aged <75 years subjected to CABG between 2002 and 2014, living within 100 km of the hospital. Key programme actions included optimization of treatments according to the most updated European preventive guidelines, surveillance of therapy adherence, and customized lifestyle counselling. Controls were analogous patients not involved in the programme because living farther than 100 km away, matched 1:1 with cases for gender, age at CABG, and year of CABG. Both groups (n = 1248) underwent usual periodic cardiology follow-up at our centre. Data on symptomatic or silent CHD recurrences were obtained from the hospital electronic health records. Cox analysis (adjusted for baseline differences between groups) shows that programme participation was associated with a significantly lower incidence throughout 5 years post-CABG of symptomatic [hazard ratio (95% confidence interval): 0.59 (0.38-0.94)] and silent [0.53 (0.31-0.89)] coronary recurrences.

Conclusion: In a real-world setting, taking part in a structured longstanding secondary prevention programme, in addition to usual cardiology care, meaningfully lowers the risk of coronary recurrences.

BackgroundRandomized evidence suggested improved outcomes in fractional flow reserve (FFR) guidance of coronary revascularization compared to medical therapy in well-defined patient cohorts. However, the impact of FFR-guided revascularization on long-term outcomes of unselected patients with chronic or acute coronary syndromes (ACS) is unknown.AimsThe FLORIDA (Fractional FLOw Reserve In cardiovascular DiseAses) study sought to investigate outcomes of FFR-guided vs. angiography-guided treatment strategies in a large, real-world cohort.MethodsThis study included patients enrolled into the German InGef Research Database. Patients undergoing coronary angiography between January 2014 and December 2015 were included in the analysis. Eligible patients had at least one inpatient coronary angiogram for suspected coronary artery disease between January 2014 and December 2015. Patients were stratified into FFR arm if a coronary angiography with adjunctive FFR measurement was performed, otherwise into the angiography-only arm. Matching was applied to ensure a balanced distribution of baseline characteristics in the study cohort. Patients were followed for 3 years after index date and primary endpoint was all-cause mortality.ResultsIn the matched population, mortality at 3 years was 9.6% in the FFR-assessed group and 12.6% in the angiography-only group (p = 0.002), corresponding to a 24% relative risk reduction with use of FFR. This effect was most pronounced in patients in whom revascularization was deferred based on FFR (8.7% vs. 12.3%, p = 0.04) and in high-risk subgroups including patients aged ≥75 years (14.9% vs. 20.1%, p 

Overview This dataset is a synthetic collection of medical attributes designed for educational and research purposes. It provides structured health-related data, including patient demographics, vital signs, and electrocardiogram (ECG) measurements, along with a predicted disease classification.

The dataset is intended to support machine learning practitioners and students in developing classification models for disease prediction. It allows users to explore patterns in health-related data and apply machine learning techniques in a controlled, educational setting.

Dataset Details Total Records: 695,551 entries Target Variable: Predicted_Disease (Categorical: ‘Arrhythmia’, ‘Heart Failure’, ‘Coronary Artery Disease’, ‘Good’)

Features: - Age - Gender - Weight - Height - Heart_Rate - Oxygen_Saturation - Temperature - ECG_QT_Interval - ECG_ST_Segment - Predicted_Disease

This dataset was generated with script with predefined parameter ranges and is not derived from real-world medical data. It should not be considered reliable for medical or clinical decision-making.

It is intended for educational purposes only and should not be used in real-world healthcare applications. The accuracy of the generated values is not guaranteed.

I'm not responsible for any incorrect use, misinterpretation, or unintended consequences of this dataset.

Percutaneous coronary interventions (PCI) have become mainstay treatment for acute coronary artery disease and the number of patients receiving PCI is vastly growing. However, relatively little long-term follow-up studies of large real-world clinical samples exist that have looked at the real-world effects of PCI treatment and adherence to current guidelines. Psychological risk factors are important in determining prognosis after PCI, and undergoing PCI may increase the risk of low mood. To date, studies have examined single psychological risk factors, without taking into account their relatedness. Moreover, guidelines are advocating psychosocial screening in early cardiovascular disease, but the screening test as proposed in the prevention guideline has not yet been validated or tested. Although the detrimental effects of psychological risk factors on cardiovascular prognosis are known, the mechanisms through which they exert these effects are yet unclear. It is to be expected that not one but multiple biological (inflammation, endothelial dysfunction) and behavioural (coping styles, poor self-care, consultation behaviour) pathophysiological processes play a role, and that these processes interact with each other. In PCI patients the mechanisms linking psychological risk to poor prognosis are still to be investigated. Objective of the study: 1. To examine the adherence to the prevention and PCI guidelines and the effects thereof on long term prognosis in PCI patients. 2. To evaluate the effectiveness of the psychosocial screening instrument of the European Society of Cardiology Prevention guideline 2012. 3. To examine effects of clustering psychological risk factors on several networks of potentially mediating mechanisms and long term outcomes in a large sample of PCI patients. Erratum in: J Affect Disord. 2018 Dec 1;241:636. PMID: 29704656.

Electrocardiogram (ECG) and Phonocardiogram (PCG) play important roles in early prevention and diagnosis of cardiovascular diseases. As the development of machine learning technique, detection of cardiovascular diseases from ECG and PCG has been attracted much attention. However, current available methods are mostly based on single data resource. It is desirable to develop efficient multi-modal machine learning methods to predict and diagnose cardiovascular diseases. In this study, we propose a novel multi-modal method for predicting cardiovascular diseases based on ECG and PCG features. By building up conventional neural networks, we extract ECG and PCG deep coding features respectively. The genetic algorithm is used to screen the combined features and obtain the best feature subset. Then support vector machine makes classification decision. Experimental results show that compared with using single-modal features ECG and PCG, the performance of this method reaches an AUC value of 0.936 when using multi-modal data resources.

This dataset is developed from a real-world dataset which was assembled by PhysioNet/CinC Challenge in 2016. The original dataset can be downloaded from website (http://www.physionet.org/challenge/2016/).

Aims: Patients with coronary heart disease (CHD) are at very high risk of recurrent events. A strategy to reduce excess risk might be to deliver structured secondary prevention programmes, but their efficacy has been mostly evaluated in the short term and in experimental settings. This is a retrospective case–control study aimed at assessing, in the real world, the efficacy of a secondary prevention programme in reducing long-term coronary event recurrences after coronary artery bypass surgery (CABG).

Methods and results: Programme participants (henceforth ‘cases’) were men and women aged <75 years subjected to CABG between 2002 and 2014, living within 100 km of the hospital. Key programme actions included optimization of treatments according to the most updated European preventive guidelines, surveillance of therapy adherence, and customized lifestyle counselling. Controls were analogous patients not involved in the programme because living farther than 100 km away, matched 1:1 with cases for gender, age at CABG, and year of CABG. Both groups (n = 1248) underwent usual periodic cardiology follow-up at our centre. Data on symptomatic or silent CHD recurrences were obtained from the hospital electronic health records. Cox analysis (adjusted for baseline differences between groups) shows that programme participation was associated with a significantly lower incidence throughout 5 years post-CABG of symptomatic [hazard ratio (95% confidence interval): 0.59 (0.38–0.94)] and silent [0.53 (0.31–0.89)] coronary recurrences.

Conclusion: In a real-world setting, taking part in a structured longstanding secondary prevention programme, in addition to usual cardiology care, meaningfully lowers the risk of coronary recurrences.

Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters Market Outlook

According to our latest research, the global Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters market size stood at USD 1.78 billion in 2024, demonstrating a robust expansion trajectory. The market is expected to grow at a CAGR of 8.3% during the forecast period, reaching a projected value of USD 3.46 billion by 2033. This growth is primarily driven by the rising prevalence of cardiovascular diseases worldwide, as well as the increasing adoption of minimally invasive procedures for coronary and peripheral artery disease management.

One of the most significant growth drivers for the Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters market is the escalating incidence of coronary artery disease and peripheral artery disease, particularly among aging populations and individuals with risk factors such as diabetes, obesity, and hypertension. The demand for effective, minimally invasive treatment options has surged as patients and clinicians seek alternatives to traditional stenting and surgical interventions. DEB catheters offer the unique advantage of delivering antiproliferative drugs directly to the arterial wall, reducing restenosis rates and improving long-term outcomes. This clinical efficacy, combined with shorter hospital stays and faster recovery times, is fueling the widespread adoption of DEB catheters across diverse healthcare settings.

Technological advancements in catheter design and drug delivery mechanisms have further accelerated market growth. The development of next-generation semi-compliant and non-compliant DEB catheters, featuring enhanced flexibility, trackability, and uniform drug coating, has significantly improved procedural success rates and patient safety profiles. Regulatory approvals for novel drug formulations and device platforms, especially in the United States and Europe, have expanded the therapeutic indications for DEB catheters. Additionally, ongoing clinical trials and real-world evidence supporting the efficacy of DEB catheters in complex lesions, small vessel disease, and in-stent restenosis are expected to broaden their market potential in the coming years.

Another crucial growth factor is the increasing emphasis on healthcare infrastructure development and reimbursement support in emerging markets. Countries in Asia Pacific and Latin America are witnessing substantial investments in cardiovascular care, including the establishment of specialized cardiac centers and the integration of advanced interventional cardiology technologies. Favorable reimbursement policies for minimally invasive procedures, coupled with rising awareness among healthcare professionals and patients, are creating new opportunities for market expansion. The global shift towards value-based healthcare and the prioritization of patient-centric treatment modalities are expected to further drive the adoption of DEB catheters worldwide.

From a regional perspective, North America and Europe collectively account for the largest share of the global Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters market, supported by high healthcare expenditure, a strong presence of leading manufacturers, and early adoption of innovative technologies. However, the Asia Pacific region is poised to register the fastest growth during the forecast period, fueled by a rising burden of cardiovascular diseases, expanding healthcare access, and increasing procedural volumes in countries such as China and India. Latin America and the Middle East & Africa are also emerging as promising markets, albeit from a smaller base, as local healthcare systems modernize and awareness of minimally invasive cardiology solutions grows.

Product Type Analysis

Within the Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters market, product type segmentation plays a pivotal role in shaping mark

BackgroundIn recent decades, the world watched a dramatic increase in the incidence of acute coronary syndromes (ACS) among young individuals (≤55 years-old) and a relative decrease in the elderly. The management of ACS in young patients with multivessel disease still needs to be elucidated, as these individuals maintain a long life expectancy.Research QuestionTo compare clinical outcomes and care costs in individuals with premature ACS and multivessel disease undergoing coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI).Methods and ResultsParticipants included all individuals ≤55 years-old admitted with ACS to public hospitals in Brasília (Brazil) between 2013 and 2015 and who underwent cardiac catheterization with SYNTAX score ≥23 or Duke category 6. Outcomes were adjudicated with death certificates and data from medical records. The primary outcome was the occurrence of major adverse cardiovascular events (MACE), defined as death due to cardiovascular causes, recurrent hospitalizations due to cardiovascular ischemic events, and incident heart failure New York Heart Association III-IV. As secondary outcome we assessed indirect and direct costs by evaluating the cost of lost productivity (in international dollars (Int$) per year) due to illness and death, outpatient costs and costs with new hospitalizations. Multivariate and principal components (PC) adjusted analyzes were performed.ResultsAmong 1,088 subjects (111 CABG and 977 PCI) followed for 6.2 years (IQR: 1.1), 304 primary events were observed. MACE was observed in 20.7% of the CABG group and 28.8% of the PCI group (p = 0.037). In multivariate analyses, PCI was associated with a hazard ratio (HR) = 1.227 (95% CI: 1.004–1.499; p = 0.0457) for MACE, and in PC-adjusted HR = 1.268 (95% CI: 1.048–1.548; p = 0.0271) compared with CABG. Despite direct costs were equivalent, the cost due to the loss of labor productivity was higher in the PCI group (Int$ 4,511 (IQR: 18,062)/year vs Int$ 3,578 (IQR: 13,198)/year; p = 0.049], compared with CABG.ConclusionsAmong young individuals with ACS and multivessel disease, surgical strategy was associated with a lower occurrence of MACE and lower indirect costs in the long-term.

Percutaneous coronary interventions (PCI) have become mainstay treatment for acute coronary artery disease and the number of patients receiving PCI is vastly growing. However, relatively little long-term follow-up studies of large real-world clinical samples exist that have looked at the real-world effects of PCI treatment and adherence to current guidelines. Psychological risk factors are important in determining prognosis after PCI, and undergoing PCI may increase the risk of low mood. To date, studies have examined single psychological risk factors, without taking into account their relatedness. Moreover, guidelines are advocating psychosocial screening in early cardiovascular disease, but the screening test as proposed in the prevention guideline has not yet been validated or tested. Although the detrimental effects of psychological risk factors on cardiovascular prognosis are known, the mechanisms through which they exert these effects are yet unclear. It is to be expected that not one but multiple biological (inflammation, endothelial dysfunction) and behavioural (coping styles, poor self-care, consultation behaviour) pathophysiological processes play a role, and that these processes interact with each other. In PCI patients the mechanisms linking psychological risk to poor prognosis are still to be investigated. Objective of the study: 1. To examine the adherence to the prevention and PCI guidelines and the effects thereof on long term prognosis in PCI patients. 2. To evaluate the effectiveness of the psychosocial screening instrument of the European Society of Cardiology Prevention guideline 2012. 3. To examine effects of clustering psychological risk factors on several networks of potentially mediating mechanisms and long term outcomes in a large sample of PCI patients.

Context

Cardiovascular disease (CVD) is a major cause of mortality in adults with type 1 diabetes.

Objective

We prospectively evaluated CVD risk factors in a large, contemporary cohort of adults with type 1 diabetes living in the United States.

Design

Observational study of CVD and CVD risk factors over a median of 5.3 years.

Setting

The T1D Exchange clinic network.

Patients

Adults (age ≥18 years) with type 1 diabetes and without known CVD diagnosed before or at enrollment.

Main Outcome Measure

Associations between CVD risk factors and incident CVD were assessed by multivariable logistic regression.

Results

The study included 8,727 participants (53% female, 88% non-Hispanic white, median age 33 years [IQR=21, 48], type 1 diabetes duration 16 years [IQR=9, 26]). At enrollment, median HbA1c was 7.6% (66 mmol/mol) [IQR=6.9 (52), 8.6 (70)], 33% used a statin, and 37% used blood pressure medication. Over a mean follow-up of 4.6 years, 325 (3.7%) participants developed incident CVD. Ischemic heart disease was the most common CVD event. Increasing age, BMI, HbA1c, presence of hypertension and dyslipidemia, increasing duration of diabetes, and diabetic nephropathy were associated with increased risk for CVD. There were no significant gender differences in CVD risk.

Conclusion

HbA1c, hypertension, dyslipidemia and diabetic nephropathy are important risk factors for CVD in adults with type 1 diabetes. A longer follow-up is likely required to assess the impact of other traditional CVD risk factors on incident CVD in the current era.

Real World Evidence Solutions Market size was valued at USD 1.30 Billion in 2024 and is projected to reach USD 3.71 Billion by 2031, growing at a CAGR of 13.92% during the forecast period 2024-2031.

Global Real World Evidence Solutions Market Drivers

The market drivers for the Real World Evidence Solutions Market can be influenced by various factors. These may include:

Growing Need for Evidence-Based Healthcare: Real-world evidence (RWE) is becoming more and more important in healthcare decision-making, according to stakeholders such as payers, providers, and regulators. In addition to traditional clinical trial data, RWE solutions offer important insights into the efficacy, safety, and value of healthcare interventions in real-world situations. Growing Use of RWE by Pharmaceutical Companies: RWE solutions are being used by pharmaceutical companies to assist with market entry, post-marketing surveillance, and drug development initiatives. Pharmaceutical businesses can find new indications for their current medications, improve clinical trial designs, and convince payers and providers of the worth of their products with the use of RWE. Increasing Priority for Value-Based Healthcare: The emphasis on proving the cost- and benefit-effectiveness of healthcare interventions in real-world settings is growing as value-based healthcare models gain traction. To assist value-based decision-making, RWE solutions are essential in evaluating the economic effect and real-world consequences of healthcare interventions. Technological and Data Analytics Advancements: RWE solutions are becoming more capable due to advances in machine learning, artificial intelligence, and big data analytics. With the use of these technologies, healthcare stakeholders can obtain actionable insights from the analysis of vast and varied datasets, including patient-generated data, claims data, and electronic health records. Regulatory Support for RWE Integration: RWE is being progressively integrated into regulatory decision-making processes by regulatory organisations including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The FDA's Real-World Evidence Programme and the EMA's Adaptive Pathways and PRIority MEdicines (PRIME) programme are two examples of initiatives that are making it easier to incorporate RWE into regulatory submissions and drug development. Increasing Emphasis on Patient-Centric Healthcare: The value of patient-reported outcomes and real-world experiences in healthcare decision-making is becoming more widely acknowledged. RWE technologies facilitate the collection and examination of patient-centered data, offering valuable insights into treatment efficacy, patient inclinations, and quality of life consequences. Extension of RWE Use Cases: RWE solutions are being used in medication development, post-market surveillance, health economics and outcomes research (HEOR), comparative effectiveness research, and market access, among other healthcare fields. The necessity for a variety of RWE solutions catered to the needs of different stakeholders is being driven by the expansion of RWE use cases.

This record contains raw data related to the article: Gender-associated outcomes following percutaneous coronary intervention with a third-generation, ultrathin-strut drug-eluting stent: a real-world, single-center experience. ABSTRACT Introduction. In recent years the new third-generation, ultrathin bioresorbable-polymer sirolimus-eluting stent (BP-SES), characterized by some of the thinnest struts among commercially available devices (60-80 µm) and an amorphous silicon carbide coating, has been introduced for the treatment of coronary artery disease (CAD). Aim of the present study was to assess different clinical outcomes and safety of this drug-eluting stent in male and female patients in a real-world setting. Methods. The present study is a retrospective analysis including all patients treated with BP-SES between January 2017 and December 2019 at a single, high-volume center. Follow-up was performed by outpatient visit or by telephone contact. The main study outcome was target lesion failure (TLF), defined as a composite of cardiovascular death, target vessel myocardial infarction or target lesion revascularization. Results: Overall, 66 (15.9%) female and 349 (84.1%) male patients were included; women were older (median age 70 vs. 66, p=0.003) and with lower BMI (25.0 vs. 26.1, p=0.010) compared to men, with no other relevant differences in baseline characteristics. Indication for percutaneous coronary intervention (PCI) was acute coronary syndrome in 86 (20.7%) of the cases, with no significant differences between male and female patients. A total of 558 lesions were treated with BP-SES stents, 90 in women and 468 in men (1.36 vs. 1.34 lesions per patient, p=0.83); cumulative stent length (33.6 mm vs. 38.4 mm, p=0.078) and mean stent diameter (2.92 mm vs. 3.0 mm, p=0.39) did not differ in women compared to men. Technical and clinical success was achieved in all patients. Stent thrombosis (ST) occurred in 2 (0.5%) patients, both males. TLF occurred in 10 (2.9%) men and in 2 (3.0%) women after a median follow-up of 402 days, without significant differences at log-rank analysis (2.34 events per 100 patient-years in males, 2.53 in females; p=0.80). Conclusions. Ultrathin struts BP-SES showed a safe and effective option for the treatment of CAD in both women and men, with very low ST rate and favorable long-term outcomes

BackgroundIn patients with suspected obstructive coronary artery disease (CAD), evaluation using a pre-test probability model is the key element for diagnosis; however, its accuracy is controversial. This study aimed to develop machine learning (ML) models using clinically relevant biomarkers to predict the presence of stable obstructive CAD and to compare ML models with an established pre-test probability of CAD models.MethodsEight machine learning models for prediction of obstructive CAD were trained on a cohort of 1,312 patients [randomly split into the training (80%) and internal validation sets (20%)]. Twelve clinical and blood biomarker features assessed on admission were used to inform the models. We compared the best-performing ML model and established the pre-test probability of CAD (updated Diamond-Forrester and CAD consortium) models.ResultsThe CatBoost algorithm model showed the best performance (area under the receiver operating characteristics, AUROC, 0.796, and 95% confidence interval, CI, 0.740–0.853; Matthews correlation coefficient, MCC, 0.448) compared to the seven other algorithms. The CatBoost algorithm model improved risk prediction compared with the CAD consortium clinical model (AUROC 0.727; 95% CI 0.664–0.789; MCC 0.313). The accuracy of the ML model was 74.6%. Age, sex, hypertension, high-sensitivity cardiac troponin T, hemoglobin A1c, triglyceride, and high-density lipoprotein cholesterol levels contributed most to obstructive CAD prediction.ConclusionThe ML models using clinically relevant biomarkers provided high accuracy for stable obstructive CAD prediction. In real-world practice, employing such an approach could improve discrimination of patients with suspected obstructive CAD and help select appropriate non-invasive testing for ischemia.

Bioresorbable Drug-Coated Coronary Scaffold Market Outlook

According to our latest research, the global bioresorbable drug-coated coronary scaffold market size reached USD 1.27 billion in 2024. The market is experiencing robust growth, driven by technological advancements and increasing prevalence of coronary artery diseases. With a compound annual growth rate (CAGR) of 8.9% from 2025 to 2033, the market is forecasted to reach USD 2.73 billion by 2033. This strong growth trajectory is underpinned by rising demand for minimally invasive cardiovascular procedures, ongoing clinical trials, and regulatory approvals for innovative scaffold products.

The growth of the bioresorbable drug-coated coronary scaffold market is primarily fueled by the increasing global incidence of coronary artery disease (CAD) and related cardiovascular conditions. As populations age and lifestyle-related risk factors such as obesity, hypertension, and diabetes become more prevalent, the demand for advanced, less invasive treatment options is surging. Bioresorbable scaffolds offer a unique advantage over traditional metallic stents by providing temporary vessel support and then gradually dissolving, thereby reducing long-term complications such as late stent thrombosis and the need for repeat interventions. This clinical benefit, combined with growing physician awareness and patient preference for innovative therapies, is accelerating market adoption.

Technological advancements represent another critical growth driver for the global bioresorbable drug-coated coronary scaffold market. Leading manufacturers are investing heavily in research and development to enhance scaffold design, drug delivery efficiency, and biocompatibility. Innovations such as next-generation polymer-based and composite scaffolds, as well as the use of advanced drug coatings like sirolimus and everolimus, are resulting in improved patient outcomes and broader indications for use. Furthermore, an increasing number of successful clinical trials and favorable regulatory pathways in major markets are supporting the commercialization of novel scaffold products, thereby expanding the addressable market and encouraging new entrants.

The market is also benefiting from the expansion of healthcare infrastructure and investments in cardiovascular care, particularly in emerging economies. As governments and private healthcare providers prioritize the adoption of cutting-edge medical technologies, the accessibility of bioresorbable drug-coated coronary scaffolds is improving. Additionally, the rising focus on value-based healthcare and the growing body of real-world evidence supporting the cost-effectiveness and safety of these scaffolds are influencing reimbursement policies in favor of advanced scaffold solutions. Collectively, these factors are creating a conducive environment for sustained market growth over the forecast period.

From a regional perspective, North America currently dominates the bioresorbable drug-coated coronary scaffold market, accounting for the largest revenue share in 2024. This leadership is attributed to high healthcare expenditure, advanced medical infrastructure, and early adoption of innovative cardiovascular devices. Europe follows closely, with strong growth driven by government initiatives to combat cardiovascular diseases and a supportive regulatory environment. Meanwhile, the Asia Pacific region is emerging as a high-growth market, propelled by expanding healthcare access, rising awareness of advanced treatment options, and significant investments in healthcare technology. Latin America and the Middle East & Africa are also witnessing increasing adoption, although at a relatively slower pace due to economic and infrastructural challenges.

Product Type Analysis

The product type segment of the bioresorbable drug-coated coronary scaffold market is broadly categorized into polymer-based scaffolds, metal-based scaffolds, and compos

In 2021, South Korea had the lowest rate of death from ischemic heart disease among OECD countries, with around ** deaths per 100,000 inhabitants. In comparison, there were around *** deaths due to ischemic heart disease per 100,000 population in Lithuania. Cardiovascular disease worldwide Fatty deposits accumulating in the inner wall of the coronary artery which restrict blood flow to the heart cause ischemic heart disease (IHD) and can also precipitate heart attacks and strokes. Cardiovascular risk factors such as smoking, heavy alcohol use, and unhealthy diet are more prevalent in Eastern European countries, contributing to a much higher burden of cardiovascular diseases and deaths. In Russia, the general public greatly underestimates the burden of cardiovascular diseases with the actual number of deaths over ** percent higher than what people estimate. Prevention and intervention Invasive interventions for heart disease can include surgical procedures such as heart bypass surgery- where blood is diverted around clogged parts of major arteries- which ranges in cost around the world. Other medical interventions include the use of prescribed or over-the-counter drugs, such as prescription nitrates or beta blockers, or OTC medications like aspirin. Lifestyle factors to lower blood pressure and cholesterol levels can help decrease risk of heart attacks and other cardiovascular diseases, including maintaining a healthy diet, regular physical activity, and smoking and alcohol cessation.

Recent developments include: In February 2024, Veradigm published its first Veradigm Insights Report: Cardiovascular Conditions in 2024, analyzing de-identified real-world data from 53 million cardiovascular patients. The report assesses the prevalence of cardiovascular disease (CVD) and related conditions across all U.S. states, with demographic breakdowns based on age, ethnicity, and sex. , In July 2021, Verana Health and Komodo Health partnered to integrate Komodo’s Healthcare Map into Verana’s de-identified EHR datasets, spanning over 325 million patient journeys. This collaboration aims to provide life sciences researchers with detailed insights into patient pathways, encompassing treatment histories, hospitalizations, and socioeconomic factors. The partnership is expected to enhance research efforts in ophthalmology, neurology, and urology by combining clinical outcomes with real-world patient data, supporting more informed treatment development. , In September 2024, ICON announced a collaboration with Intel to utilize de-identified data from its clinical research platform alongside Intel's AI technology. This partnership enhances patient recruitment and streamlines clinical trial processes by deriving insights from de-identified patient data. The initiative aims to advance precision medicine and improve efficiencies in drug development and outcomes by integrating ICON's clinical trial expertise with Intel's AI capabilities. .

Library of Wroclaw University of Science and Technology scientific output (DONA database)

Background: Participants in clinical trials frequently fail to appreciate key differences between research and clinical care. This phenomenon, known as therapeutic misconception, undermines informed consent to clinical research, but to date there have been no effective interventions to reduce it and concerns have been expressed that to do so might impede recruitment. We determined whether a scientific reframing intervention reduces therapeutic misconception without significantly reducing willingness to participate in hypothetical clinical trials. Methods: This prospective randomized trial was conducted from 2015 to 2016 to test the efficacy of an informed consent intervention based on scientific reframing compared to a traditional informed consent procedure (control) in reducing therapeutic misconception among patients considering enrollment in hypothetical clinical trials modeled on real-world studies for one of five disease categories. Patients with diabetes mellitus, hypertension, coronary artery disease, head/neck cancer, breast cancer, and major depression were recruited from medical clinics and a clinical research volunteer database. The primary outcomes were therapeutic misconception, as measured by a validated, ten-item Therapeutic Misconception Scale (range=10-50), and willingness to participate in the clinical trial. Results: 154 participants completed the study (age range, 23-87 years; 92.3% white, 56.5% female); 74 (48.1%) had been randomized to receive the experimental intervention. Therapeutic misconception was significantly lower (p=0.004) in the scientific reframing group (26.4, 95% CI [23.7 to 29.1] compared to the control group (30.9, 95% CI [28.4 to 33.5], and remained so after controlling for education (p=0.017). Willingness to participate in the hypothetical trial was not significantly different (p=0.603) between intervention (52.1%, 95% CI [40.2 to 62.4]) and control (56.3%, 95% CI [45.3 to 66.6] groups. Conclusions: An enhanced educational intervention augmenting traditional informed consent led to a meaningful reduction in therapeutic misconception without a statistically significant change in willingness to enroll in hypothetical clinical trials. Additional study of this intervention is required in real-world clinical trials.

The Virtual Clinical Trials (VCT) market is experiencing rapid growth, driven by the increasing need for efficient, cost-effective, and accessible clinical research. Market segmentation reveals key trends across study design, therapeutic indication, and technological advancements. By study design, the market is categorized into interventional, observational, and expanded access trials. While interventional trials currently dominate due to their efficacy and safety assessment capabilities, the demand for more agile and flexible trial designs is boosting the growth of observational studies and expanded access programs. This is particularly true in the realm of real-world data collection and analysis.In terms of therapeutic indications, oncology and cardiovascular disease maintain the largest market share, reflecting the high prevalence of these conditions and the ongoing pursuit of novel treatment modalities. Within oncology, solid tumors and hematological malignancies represent key therapeutic areas, while the cardiovascular segment encompasses coronary artery disease, heart failure, and arrhythmias. Beyond these major segments, significant growth potential exists within neurology, infectious diseases, rare diseases, and respiratory disorders, fueled by unmet medical needs and technological advancements enabling efficient patient recruitment and data acquisition in these complex therapeutic areas.Industry collaborations are significantly impacting market dynamics. Strategic partnerships between pharmaceutical companies, technology providers, and Contract Research Organizations (CROs) are fostering innovation, integrating advanced technologies, and expanding the capabilities of VCTs. The adoption of artificial intelligence (AI) for data analysis, wearable sensors for continuous patient monitoring, and remote patient engagement platforms are streamlining trial processes, reducing costs, and improving patient adherence and overall trial efficiency. This increased efficiency leads to faster time-to-market for new therapies and ultimately, improved patient outcomes. Recent developments include: In July 2023, Signant Health completed the acquisition of DSG, strategically augmenting its eClinical solution suite for both traditional and decentralized clinical trials. By integrating DSG's unified platform, the acquisition facilitated the development of a comprehensive trial ecosystem equipped with advanced software, analytics, and logistics solutions, enabling seamless study conduct and data generation across all modalities, thereby accomplishing the goal of fully digitalizing clinical trials. , In June 2023, Medable Inc. unveiled a comprehensive toolkit tailored for Institutional Review Boards (IRBs)/Ethics Committees (ECs), designed to establish standardized ethics review procedures for decentralized clinical trials (DCTs). The implementation of this toolkit successfully simplified, streamlined, and accelerated the IRB/EC process, playing a pivotal role in fostering enhanced efficiency and patient-centeredness in the execution of DCTs. , In October 2022, Oracle and ObvioHealth entered into a strategic collaboration to integrate diverse data sets into virtual/decentralized clinical trials in the Asia Pacific region. This initiative is expected to allow the quick collection, integration and analysis of multi-source data collected from labs, devices, patients, and sites. .